DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
Combretastatin is an investigational drug.
There have been 19 clinical trials for Combretastatin. The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Thyroid Carcinoma, Anaplastic, Thyroid Neoplasms, and Thyroid Diseases. The leading clinical trial sponsors are Mateon Therapeutics, National Cancer Institute (NCI), and Case Comprehensive Cancer Center.
There are two US patents protecting this investigational drug and fifteen international patents.
Recent Clinical Trials for Combretastatin
|FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer||Mateon Therapeutics||Phase 2/Phase 3|
|Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS||Mateon Therapeutics||Phase 1/Phase 2|
|Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer||Mateon Therapeutics||Phase 3|
Top disease conditions for Combretastatin
Top clinical trial sponsors for Combretastatin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Combretastatin||Start Trial||Anti-FGFR3 antibodies and methods using same||Genentech, Inc. (South San Francisco, CA)||Start Trial|
|Combretastatin||Start Trial||Method of diagnosing and treating cancer using B-catenin splice variants||The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC)||Start Trial|
|Combretastatin||Start Trial||Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers||Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|